Christopher Seder to Mass Screening
This is a "connection" page, showing publications Christopher Seder has written about Mass Screening.
Connection Strength
0.187
-
Lung cancer screening is here to stay, but does it pay? J Thorac Cardiovasc Surg. 2018 01; 155(1):426-427.
Score: 0.139
-
The role of IGF-pathway biomarkers in determining risks, screening, and prognosis in lung cancer. Oncotarget. 2022; 13:393-407.
Score: 0.047